Antiplatelet activity and TNF- α release inhibition of phthalimide derivatives useful to treat sickle cell anemia

AbstractSickle Cell Anemia (SCA) is one of the most prevalent hereditary hematological diseases worldwide. The disease is characterized by chronic inflammation, hypercoagulable state, and pro-thrombotic profile, which lead the vaso-occlusive process. In this work, we described the antiplatelet activity and the ability to reduce tumor necrosis factor-alpha (TNF- α) levels of phthalimide derivatives. All compounds inhibited platelet aggregation induced by collagen and adenosine diphosphate, at levels ranging from 26.0 to 74.2% and 30.7 to 79.6%, respectively. The compounds exhibited reduced bleeding time compared to acetylsalicylic acid (ASA). Moreover, com pounds4c and10c inhibited TNF- α levels at 73.5% and 65.0%, respectively. These findings suggest that phthalimide derivatives4c and10c are promising lead compounds useful to prevent vaso-occlusion and inflammation associated with the sickle cell anemia.
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research